Interaction of arsenic trioxide and etoposide in Ewing sarcoma cell lines

Lenz,Julia   E.; Riester,Rosa; Schleicher,Sabine   B.; Handgretinger,Rupert; Boehme,Karen   A.; Traub,Frank

doi:10.3892/or.2019.7409

Interaction of arsenic trioxide and etoposide in Ewing sarcoma cell lines

Authors:
- Julia E. Lenz
- Rosa Riester
- Sabine B. Schleicher
- Rupert Handgretinger
- Karen A. Boehme
- Frank Traub
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Eberhard Karls University Tuebingen, D‑72076 Tuebingen, Germany, Department of Orthopaedic Surgery, Laboratory of Cell Biology, Eberhard Karls University Tuebingen, D‑72072 Tuebingen, Germany, Department of Hematology and Oncology, Children's Hospital, Eberhard Karls University Tuebingen, D‑72076 Tuebingen, Germany
Published online on: November 20, 2019 https://doi.org/10.3892/or.2019.7409
Pages: 337-345

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ewing sarcomas (ES) are highly malignant mesenchymal tumors, which most often occur in children and adolescents. The current treatment of choice comprises wide resection in combination with multimodal chemotherapy including etoposide (Eto). Due to the serious side effects associated with common chemotherapeutics and prevalent multidrug resistance in recurrent and metastatic ES, there is a growing demand for alternative strategies and add‑on drugs. Previous research has demonstrated efficient cell death induction by Eto in combination with arsenic trioxide (ATO) in ES cell lines. The aim of the present study was to investigate the effect of different temporal sequences of ATO and Eto administration on apoptosis induction and to explore the effect of both drugs on inhibitory glycogen synthase kinase‑3β (GSK3‑β) phosphorylation as well as multidrug transporter gene expression. The intensity of caspase activation was mainly determined by the Eto doses in A673 and TC‑71 cells, whereas in RD‑ES cells ATO application actively suppressed Eto‑induced apoptosis. This coincided with an increase in inhibitory GSK‑3β phosphorylation in ATO‑treated RD‑ES cells. Inherent mRNA expression of multidrug resistance‑associated protein 1 (MRP1) was low in the ES cell lines compared to that observed in the mesenchymal stem cells (MSC), whereas multidrug resistance protein 1 (MDR1) gene expression was considerably increased in the ES cell lines. ATO treatment reduced MRP1 mRNA expression in the A673 and TC‑71 cells, while expression was induced in the MSC and RD‑ES cells. In contrast, MDR1 mRNA expression was specifically induced by ATO in the A673 and TC‑71 cells, reinforcing the expression differences between MSC and the ES cell lines. Although a reliable cell death induction by the combination of ATO and Eto has been previously shown in ES cell lines, the present study showed marked heterogeneity of the ES cell response to ATO and Eto treatment, illustrating the difficulty of prediction of individual treatment outcome in ES.

View Figures

View References

1	Ross KA, Smyth NA, Murawski CD and Kennedy JG: The biology of Ewing sarcoma. ISRN Oncol. 2013:7597252013.PubMed/NCBI
2	Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P and Delattre O: Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 11:421–429. 2007. View Article : Google Scholar : PubMed/NCBI
3	Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J and Uren A: GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem. 284:9074–9082. 2009. View Article : Google Scholar : PubMed/NCBI
4	Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E, et al: Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene. 36:3505–3514. 2017. View Article : Google Scholar : PubMed/NCBI
5	Boehme KA, Nitsch J, Riester R, Handgretinger R, Schleicher SB, Kluba T and Traub F: Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. Int J Oncol. 49:2135–2146. 2016. View Article : Google Scholar : PubMed/NCBI
6	Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, et al: Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/GLI pathway. J Clin Invest. 121:148–160. 2011. View Article : Google Scholar : PubMed/NCBI
7	Sand LG, Szuhai K and Hogendoorn PC: Sequencing overview of Ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci. 16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
8	May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER and Reynolds CP: Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 8:e800602013. View Article : Google Scholar : PubMed/NCBI
9	Oda Y, Dockhorn-Dworniczak B, Jürgens H and Roessner A: Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol. 123:237–239. 1997. View Article : Google Scholar : PubMed/NCBI
10	Roundhill EA and Burchill SA: Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br J Cancer. 106:1224–1233. 2012. View Article : Google Scholar : PubMed/NCBI
11	Roessner A, Ueda Y, Bockhorn-Dworniczak B, Blasius S, Peters A, Wuisman P, Ritter J, Paulussen M, Jürgens H and Böcker W: Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol. 119:185–189. 1993. View Article : Google Scholar : PubMed/NCBI
12	Mauz-Körholz C, Kachel M, Harms-Schirra B, Klein-Vehne A, Tunn PU and Körholz D: Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells. Anticancer Res. 24:145–149. 2004.PubMed/NCBI
13	Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, et al: ESMO Guidelines Committee, paedcan and ERN EURACAN: Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv79–iv95. 2018. View Article : Google Scholar : PubMed/NCBI
14	Clifford B, Beljin M, Stark GR and Taylor WR: G2 arrest in response to topoisomerase II inhibitors: The role of p53. Cancer Res. 63:4074–4081. 2003.PubMed/NCBI
15	Lin CF, Tsai CC, Huang WC, Wang YC, Tseng PC, Tsai TT and Chen CL: Glycogen synthase kinase-3β and caspase-2 mediate ceramide- and etoposide-induced apoptosis by regulating the lysosomal-mitochondrial axis. PLoS One. 11:e01454602016. View Article : Google Scholar : PubMed/NCBI
16	Lee KI, Su CC, Yang CY, Hung DZ, Lin CT, Lu TH, Liu SH and Huang CF: Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 36:142–152. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ngok-Ngam P, Watcharasit P, Thiantanawat A and Satayavivad J: Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett. 18:58–74. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lengfelder E, Hofmann WK and Nowak D: Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 26:433–442. 2012. View Article : Google Scholar : PubMed/NCBI
19	Boehme KA, Zaborski JJ, Riester R, Schweiss SK, Hopp U, Traub F, Kluba T, Handgretinger R and Schleicher SB: Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. Int J Oncol. 48:801–812. 2016. View Article : Google Scholar : PubMed/NCBI
20	Au WY, Tam S, Fong BM and Kwong YL: Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 112:3587–3590. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, Cho CK, Park IC, Park MJ, Rhee CH, et al: Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: Reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res. 64:8960–8967. 2004. View Article : Google Scholar : PubMed/NCBI
22	Beauchamp EM and Uren A: A new era for an ancient drug: Arsenic trioxide and Hedgehog signaling. Vitam Horm. 88:333–354. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dawood M, Hamdoun S and Efferth T: Multifactorial modes of action of arsenic trioxide in cancer cells as analyzed by classical and network pharmacology. Front Pharmacol. 9:1432018. View Article : Google Scholar : PubMed/NCBI
24	Chiu HW, Tseng YC, Hsu YH, Lin YF, Foo NP, Guo HR and Wang YJ: Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. Cancer Lett. 356:762–772. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kozono S, Lin YM, Seo HS, Pinch B, Lian X, Qiu C, Herbert MK, Chen CH, Tan L, Gao ZJ, et al: Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 9:30692018. View Article : Google Scholar : PubMed/NCBI
26	Jiang L, Wang L, Chen L, Cai GH, Ren QY, Chen JZ, Shi HJ and Xie YH: As2O3 induces apoptosis in human hepatocellular carcinoma HepG2 cells through a ROS-mediated mitochondrial pathway and activation of caspases. Int J Clin Exp Med. 8:2190–2196. 2015.PubMed/NCBI
27	Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS and Liu SH: Arsenic induces apoptosis in myoblasts through a reactive oxygen species-induced endoplasmic reticulum stress and mitochondrial dysfunction pathway. Arch Toxicol. 86:923–933. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kumar S, Yedjou CG and Tchounwou PB: Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 33:422014. View Article : Google Scholar : PubMed/NCBI
29	States JC: Disruption of mitotic progression by arsenic. Biol Trace Elem Res. 166:34–40. 2015. View Article : Google Scholar : PubMed/NCBI
30	Huang HS, Liu ZM and Cheng YL: Involvement of glycogen synthase kinase-3β in arsenic trioxide-induced p21 expression. Toxicol Sci. 121:101–109. 2011. View Article : Google Scholar : PubMed/NCBI
31	Schleicher SB, Zaborski JJ, Riester R, Zenkner N, Handgretinger R, Kluba T, Traub F and Boehme KA: Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. PLoS One. 12:e01788572017. View Article : Google Scholar : PubMed/NCBI
32	Beurel E and Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 79:173–189. 2006. View Article : Google Scholar : PubMed/NCBI
33	Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Müller I, Schewe B, Skutella T, Fibbe WE, et al: Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 94:173–184. 2009. View Article : Google Scholar : PubMed/NCBI
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
35	Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I and Szijan I: Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med. 16:262–270. 2010. View Article : Google Scholar : PubMed/NCBI
36	Xie J, Li DW, Chen XW, Wang F and Dong P: Expression and significance of hypoxia-inducible factor-1α and MDR1/P- glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol Lett. 6:232–238. 2013. View Article : Google Scholar : PubMed/NCBI
37	König J, Hartel M, Nies AT, Martignoni ME, Guo J, Büchler MW, Friess H and Keppler D: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer. 115:359–367. 2005. View Article : Google Scholar : PubMed/NCBI
38	Benaitreau D, Dieudonné MN, Dos Santos E, Leneveu MC, Mazancourt PD and Pecquery R: Antiproliferative effects of adiponectin on human trophoblastic cell lines JEG-3 and BeWo. Biol Reprod. 80:1107–1114. 2009. View Article : Google Scholar : PubMed/NCBI
39	Amable L, Gavin E, Kudo K, Meng E, Rocconi RP, Shevde LA and Reed E: GLI1 upregulates C-JUN through a specific 130-kDa isoform. Int J Oncol. 44:655–661. 2014. View Article : Google Scholar : PubMed/NCBI
40	McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, et al: GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 5:2881–2911. 2014. View Article : Google Scholar : PubMed/NCBI
41	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
42	Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P and Kovar H: A molecular function map of Ewing's sarcoma. PLoS One. 4:e54152009. View Article : Google Scholar : PubMed/NCBI
43	Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL and Beckerle MC: Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell. 25:2695–2709. 2014. View Article : Google Scholar : PubMed/NCBI
44	McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP and Boise LH: Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther. 2:1155–1164. 2003.PubMed/NCBI
45	Scholz C, Wieder T, Stärck L, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT: Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene. 24:1904–1913. 2005. View Article : Google Scholar : PubMed/NCBI
46	Raju GP: Arsenic: A potentially useful poison for hedgehog-driven cancers. J Clin Invest. 121:14–16. 2011. View Article : Google Scholar : PubMed/NCBI
47	Yang K, Chen Z, Gao J, Shi W, Li L, Jiang S, Hu H, Liu Z, Xu D and Wu L: The Key roles of GSK-3β in regulating mitochondrial activity. Cell Physiol Biochem. 44:1445–1459. 2017. View Article : Google Scholar : PubMed/NCBI
48	Shukalek CB, Swanlund DP, Rousseau RK, Weigl KE, Marensi V, Cole SP and Leslie EM: Arsenic triglutathione [As(GS)3] transport by multidrug resistance protein 1 (MRP1/ABCC1) is selectively modified by phosphorylation of Tyr920/Ser921 and glycosylation of Asn19/Asn23. Mol Pharmacol. 90:127–139. 2016. View Article : Google Scholar : PubMed/NCBI
49	Maciaszczyk-Dziubinska E, Wawrzycka D and Wysocki R: Arsenic and antimony transporters in eukaryotes. Int J Mol Sci. 13:3527–3548. 2012. View Article : Google Scholar : PubMed/NCBI
50	Seo T, Urasaki Y and Ueda T: Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int J Hematol. 85:26–31. 2007. View Article : Google Scholar : PubMed/NCBI
51	Santisteban M: ABC transporters as molecular effectors of pancreatic oncogenic pathways: The Hedgehog-GLI model. J Gastrointest Cancer. 41:153–158. 2010. View Article : Google Scholar : PubMed/NCBI
52	Erdei Z, Lőrincz R, Szebényi K, Péntek A, Varga N, Likó I, Várady G, Szakács G, Orbán TI, Sarkadi B and Apáti A: Expression pattern of the human ABC transporters in pluripotent embryonic stem cells and in their derivatives. Cytometry B Clin Cytom. 86:299–310. 2014. View Article : Google Scholar : PubMed/NCBI
53	Brown HK, Schiavone K, Gouin F, Heymann MF and Heymann D: Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int. 102:174–195. 2018. View Article : Google Scholar : PubMed/NCBI
54	Yu H, Ge Y, Guo L and Huang L: Potential approaches to the treatment of Ewing's sarcoma. Oncotarget. 8:5523–5539. 2017.PubMed/NCBI